medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Number 4

<< Back Next >>

Rev Latin Infect Pediatr 2018; 31 (4)

Extract from the «Chapter on the control and diagnosis of the child exposed to HIV of the consensus document for the monitoring of HIV infection in relation to reproduction, pregnancy, childbirth and prophylaxis of vertical transmission of the exposed child»

González TMI Antoni NJ

Language: Spanish
References: 29
Page: 131-139
PDF size: 271.57 Kb.


ABSTRACT

Early identification of HIV infection in women efficiently prevents mother-to-child transmission, provided that we ensure access to antiretroviral treatment, obstetric care and adequate information by health-care providers. The neonatal antiretroviral prophylaxis from the very first hours of life is also a key point in the prevention of transmission, being vital the adequate selection of the regimen to be administered to the newborn considering the risk factor that the patient presents. Currently, most of the guidelines advocate for triple therapy in case of presenting risk factors for HIV acquisition. The follow-up for the diagnosis of the infection in the neonate will depend on their age. It is recommended to use viral screening tests in the first months of life, since months the maternal antibodies transferred through the placenta can persist up to 12-18 months of age. Also, other coinfections should be also studied as well as the possible side effects associated with the use of antiretrovirals that the medical personnel must be able to recognize. Finally, the avoidance of breastfeeding in countries with resources to provide artificial feeding is another factor of protection.


REFERENCES

  1. ONUSIDA. Estadísticas mundiales sobre el VIH de 2017. Accesible en: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_es.pdf

  2. Grupo de expertos de la Secretaría del Plan Nacional sobre el Sida (SPNS), Grupo de Estudio de Sida (GeSIDA)/Sociedad Española de Ginecología y Obstetricia (SEGO) y Sociedad Española de Infectología Pediátrica (SEIP). Documento de consenso para el seguimiento de la infección por el VIH en relación con la reproducción, embarazo, parto y profilaxis de la transmisión vertical del niño expuesto. Enero de 2018. Accesible en: http://gesida-seimc.org/wp-content/uploads/2018/01/gesida_borrador_9_ene_GUIA_PRACTICA_PARA_EL_SEGUIMIENTO_DE_LA_INFECCION_POR_VIH_EN_LA_REPRODUCCION.pdf

  3. Panel on Treatment of HIV-infected pregnant women and prevention of perinatal transmission. recommendations for use of antiretroviral drugs in pregnant HIV-1-Infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available in: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Last access (March 2017).

  4. De Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G et al. British HIV Association and Children’s HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008; 9 (7): 452-502.

  5. Burgard M, Blanche S, Jasseron C, Descamps P, Allemon MC, Ciraru-Vigneron N et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 2012; 160 (1): 60-6.e1.

  6. Havens PL, Mofenson LM and the Committee on Pediatric AIDS. Evaluation and Management of the Infant Exposed to HIV-1 in the United States. Pediatrics. 2009; 123: 175-187.

  7. Read JS and the Committee on Pediatric AIDS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 2007; 120 (6): 1547-1562.

  8. Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015; 61 (11): 1715-1725.

  9. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998; 339 (20): 1409-1414.

  10. Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH et al. NICHD HPTN040/PACTG 1043 Protocol Team. Three postpartum antiretroviral regimens to preventintrapartum HIV infection. N Engl J Med. 2012; 366 (25): 2368-2379.

  11. Prieto LM, González-Tomé MI, Muñoz E, Fernández-Ibieta M, Soto B, Del Rosal T et al. Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000-2007. Pediatr Infect Dis J. 2012; 31 (10): 1053-1058.

  12. Kakkar FW, Samson L, Vaudry W, Brophy J, Le Meur JB, Lapointe N et al. Safety of combination antiretroviral prophylaxis in high-risk HIV-exposed newborns: a retrospective review of the Canadian experience. J Int AIDS Soc. 2016; 19 (1): 20520.

  13. Chadwick EG, Qin M, Bryson Y et al. Establishing a treatment dose of nevirapine for full-term neonates with perinatal HIV infection: IMPAACTP1115. 21st International AIDS Conference; July 18-22, 2016; Durban, South Africa; LBPE011.

  14. Bolaris MA, Keller MA, Robbins BL, Podany AT, Fletcher CV. Nevirapine plasma concentrations in human immunodeficiency virus-exposed neonates receiving high-dose nevirapine prophylaxis as part of 3-drug regimen. J Pediatric Infect Dis Soc. 2017; 6 (1): 102-104.

  15. Lau E, Brophy J, Samson L, Kakkar F, Campbell DM, Yudin MH et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission. J Acquir Immune Defic Syndr. 2017; 74 (5): 493-498.

  16. Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM et al. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014; 67 (3): 310-315.

  17. Clarke DF, Acosta EP, Chain A, Cababasay M, Wang J, Calabrese K et al. IMPAACT P1110: raltegravir pharmacokinetics and safety in hiv-1 exposed neonates: dose-finding study. Conference on Retroviruses and Opportunistic Infection 2017, In: Seattle (EEUU) 13 ta 16 from February of 2017. Available in http://impaactnetwork.org/DocFiles/CROI2017/P1110_Clarke_CROI2017_poster.pdf

  18. Boxwell D, Cao K, Lewis L, Marcus K, Nikhar B. Neonatal toxicity of Kaletra oral solution: LPV, ethanol or prophylene glycol? 18th Conference on Retrovirus and Opportunistic Infections. Boston MA 2011.

  19. Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016; 387 (10018): 566-573.

  20. Bauer GR, Colgrove RC, Larussa PS, Pitt J, Welles SL. Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants. AIDS. 2006; 20 (13): 1707-1712.

  21. De Jose MI, Ramos JT, Alvarez S, Jimenez JL, Muñoz-Fernández MA. Vertical transmission of HIV-1 variants resistant to reverse transcriptase and protease inhibitors. Arch Intern Med. 2001; 161 (22): 2738-2739.

  22. Capretti MG, Marsico C, Conti M, Corvaglia LT, Arcuri S, Faldella G et al. Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants. New Microbiol. 2016; 39 (4): 314-316.

  23. Mugabo P, Els I, Smith J, Rabie H, Smith P, Mirochnick M et al. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. S Afr Med J. 2011; 101 (9): 655-658.

  24. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004; 18 (17): 2337-2339.

  25. World Health Organization. Statement on DTG-Geneva 18 May 2018. Access in: http://www.who.int/medicines/publications/dugalets/Statement_on_DTG_18May_2018finaua=1

  26. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ et al. Reduction of maternal-infant transmission of Human Immunodeficiency Virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group 076 Study Group. N Engl J Med. 1994; 331: 1173-1180.

  27. Noguera-Julian A, Morén C, Rovira N, Garrabou G, Catalán M, Sánchez E et al. Decreased mitochondrial function among healthy infants exposed to antiretrovirals during gestation, delivery and the neonatal period. Pediatr Infect Dis J. 2015; 34 (12): 1349-1354.

  28. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA. 2011; 305 (6): 576-584.

  29. Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in hiv-1-infected women with high CD4 Cell Count (IMPAACT PROMISE): a randomized, open-label, clinical trial. J Acquir Immune Defic Syndr. 2018; 77 (4): 383-392.




2020     |     www.medigraphic.com